Danish pharmaceutical company LEO Pharma has gained approval to market its new scalp psoriasis drug Xamiol in Europe, writes financial daily newspaper Børsen. Sources with knowledge of the psoriasis market estimate that Xamiol could generate sales of more than DKK 1bn (USD 200m) over a number of years, while LEO Pharma is not putting specific numbers on its expectations:
"There is a significant market potential for Xamiol," said LEO Pharma CEO Gitte P. Aabo to Børsen.
In June, LEO Pharma's new product was approved for the US market, where it has been launched under the name Talconex Scalp by partner Warner Chilcott. Xamiol is expected to be launched in the UK in Q4 2008.
According to Børsen it has been difficult to find an effective treatment for scalp psoriasis and so far patients have had to be treated with drugs that are applied to the scalp several times during the day. With LEO Pharma's new drug, patients need only apply it in the evening, and it can be washed out again the following morning.
In Europe and the US there are about 20 million adults who suffer from psoriasis, and approx. 450,000 new cases of the disease are diagnosed each year. It is estimated that 65% of all patients suffering from psoriasis have the chronic, inflammatory disease on the body and the scalp simultaneously.
LEO Pharma, which is Denmark's oldest pharmaceutical company, is headquartered in Ballerup near Copenhagen. The company focuses on development, manufacturing and marketing of drugs for the treatment of psoriasis and other skin diseases as well as thromboembolic disorders. In 2007, LEO Pharma generated revenues of DKK 5.2bn (USD 1.02bn).